Hana Biosciences:Eine große Story nimmt ihren Lauf

Nachdem ich sie im letzten Jahr schon einmal mit schönem Erfolg hatte, bin ich nun zu 6,08€ wieder eingestiegen! Ich denke mal, dass die Korrektur nun abgeschlossen ist und es wieder nach oben geht.

Das Unternehmen ist einfach klasse. Toller Vorstand, tolle Produkte. Ist für mich kein Zock, sondern eine langfristig ganz heiße Story.

(bevor es im Thread untergeht)

Hana Biosciences to Present at the Canaccord Adams Summer Seminar
8/2/2006      

SOUTH SAN FRANCISCO, Calif., Aug 02, 2006 (BUSINESS WIRE) --
Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Canaccord Adams Summer Seminar on Tuesday, August 8th at 3:30pm EDT in the NY Main Room at The Marriott Long Wharf Hotel in Boston, MA.

A live audio webcast of the presentation can be accessed on the company's website, www.hanabiosciences.com. An audio replay of the presentation will also be available for 90 days after the conference.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the three months ended March 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 (Investor & Media) Fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006

Hana in USA 5% vorne, Taxe hier 6,20/6,31.

Somit ist das Ask ja schon 0,23€ höher als vorhin bei meinem Kauf!:-)

www.sec.gov/cgi-bin/...e=&SIC=&owner=include&action=getcompany


Ist ja schon Einiges, was der Vorstand da angesammelt hat. Die scheinen zu wissen, was sie tun.

SK 6,23€. Fast beim Tagestief gestartet, beim Tageshoch gestoppt. So ists schön...!;-)

Interessant, dass es fast alles Askkäufe waren heute!

Und Schluss gestern in USA auf Tageshoch. Sieht klasse aus.

Man, sieht echt gut aus. Bei so einem "Schwergewicht" nach nichtmal einem Tag schon 5% vorne.

Sphingosomal encapsulation is a targeted liposomal drug delivery platform, which is designed to significantly increase tumor targeting and duration of exposure for cell cycle-specific anticancer agents. Encapsulation also allows an increase in dose intensity without increased toxicity, in preclinical studies. Vincristine, vinorelbine and topotecan are approved cancer therapies which have been selected for sphingosomal formulation specifically for their ability to benefit from this novel encapsulation.

The possible advantages of sphingosomal drug delivery include:

-- Longer circulation time in plasma delivers more of the therapeutic agent to targeted tumor sites over a longer period of time. To stabilize the lipid bilayer walls and retain active drug within the aqueous interior, this new generation liposomal technology uses sphingomyelin, a safe, biologically inert macromolecule whose amide backbone is resistant to hydrolysis. The increased rigidity of the liposomal walls prolongs the circulating life of liposomes and significantly extends the duration of drug release.

-- Slow release of the drug from extravasated sphingosomes increases drug levels within the tumor, extends drug exposure through multiple cell cycles, and significantly enhances tumor cell killing. The immature neovasculature within tumors is created during angiogenesis and has numerous imperfections, pores and discontinuities up to 800 nm in size. With an average diameter of approximately 100 nm, sphingosomes readily extravasate through these pores and accumulate within the tumor and slowly release the encapsulated drug.

-- Increased drug concentration at the tumor site is believed to be associated with increased clinical activity. The link between drug exposure and anti-tumor efficacy is especially pronounced for cell cycle-specific agents such as vincristine, vinorelbine and topotecan, which kill tumor cells by interfering with mitosis at a precise step during the cancer cell cycle. This proprietary sphingosomal drug delivery platform is designed to encapsulate these agents within the aqueous interior of small liposomes in order to enhance the therapeutic index of these existing anticancer treatments.

This sphingosome encapsulated technology was discovered at the University of British Columbia and subsequently developed by Inex Pharmaceuticals Corporation. In May 2006, Hana Biosciences licensed three drug candidates utilizing this technology from Inex.

About Non-Small Cell Lung Cancer (NSCLC)

According to the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial cancer each year, causing approximately 1.1 million deaths annually. It is estimated that more than 173,000 people will be diagnosed with lung cancer in the United States in 2005. According to the National Cancer Institute, lung cancer is the single largest cause of cancer deaths in the United States and is responsible for nearly 30 percent of cancer deaths in this country. NSCLC accounts for more than 80 percent of all lung cancers. Despite recent therapeutic advances in NSCLC, the overall survival remains poor and there is a need for improved treatments.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

About Inex Pharmaceuticals Corporation

Inex Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Since 1996, INEX common shares have been trading on the Toronto Stock Exchange under the symbol "IEX". Additional information on Inex Pharmaceuticals can be found at www.inexpharm.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the three months ended March 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 Fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006

INEX announced June 20, 2006 it had signed a definitive note purchase and settlement agreement with all of the holders of the exchangeable and development notes (the "Former Noteholders") issued by a wholly-owned subsidiary of INEX and guaranteed by INEX. Under the agreement with the Former Noteholders the up-front Hana shares were transferred to the Former Noteholders on June 20, 2006 and INEX has agreed to pay some of the future contingent Hana milestones and royalties to the Former Noteholders.

On July 17, 2006, INEX announced the acceleration of a collaboration signed March 27, 2006 with Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY). The companies are exploring the use of INEX's liposomal delivery technology for the systemic delivery of Alnylam's RNAi therapeutic products. Due to the rapid progress made so far, INEX and Alnylam have decided to move into the next phase of the collaboration, which includes investigating additional gene targets. In conjunction with this progress, Alnylam will make certain payments to INEX totalling approximately US$1.9 million, US$1.0 million of which relates to an option to license INEX's technology.

The Company announced July 18, 2006 that a shareholder meeting will occur September 20, 2006 to approve the revised Plan of Arrangement to spin out INEX's pharmaceutical assets into Tekmira. Shareholders of record on August 11, 2006 will be eligible to vote. Meeting materials will be mailed to shareholders in August 2006.


<<
Highlights of the spin-out include transferring to Tekmira:
- All of the pharmaceutical assets from INEX's two technology
platforms, Targeted Chemotherapy and Targeted Immunotherapy;
- All of INEX's cash;
- INEX's pharmaceutical partnerships with Hana and Alnylam.
>>


All of the Tekmira shares will be distributed to INEX common shareholders. INEX's current management team and employees will join Tekmira in the same positions they occupy at INEX. The Tekmira spin-out is subject to shareholder, regulatory and court approval.

Protiva dispute

Also during the second quarter, INEX announced April 28, 2006 that certain of its directors and officers filed statements of defence in response to a claim filed by Protiva Biotherapeutics Inc. in the Supreme Court of British Columbia. INEX also filed a counterclaim against Protiva.

INEX believes its legal position will prevail and that the litigation will have a negligible impact on the execution of its business plan.

The dispute with Protiva is over the rights to certain drug delivery technology for the delivery of a class of drugs called oligonucleotides, including small interfering RNA (siRNA). Protiva, a private biotechnology company, was spun out from INEX in 2001 along with certain intellectual property rights to use INEX's drug delivery technology only for the delivery of gene plasmids in the pursuit of developing gene therapy products. As part of these 2001 agreements that formed Protiva, INEX retained all rights to the delivery of olignucleotides, including siRNA. INEX holds a minority interest in Protiva.

Pursuant to rights INEX has under agreements with Protiva, INEX believes that any technology advancements made by Protiva and its collaborators or by INEX for the delivery of oligonucleotides, including siRNA, are either owned by INEX or should be licensed to INEX on an exclusive, worldwide, paid-up and royalty-free basis.

Product development milestones


<<
The goals for INEX and Tekmira for the second half of 2006 include:
- Supporting Hana to advance Marqibo into phase 3 clinical trials and
advance INX-0125 into a phase 1 clinical trial;
- Supporting Alnylam's evaluation of INEX's liposomal drug delivery
technology for the systemic delivery of Alnylam's RNAi therapeutic
products directed towards multiple gene targets;
- Presenting additional preclinical data for INX-0167 in non-human
primate studies demonstrating its potential as a potent immune
stimulant; and
- Initiating formal toxicology studies for INX-0167 in order to file
an Investigational New Drug Application in 2007 to begin clinical
trials.
>>


Financial Results

For the six months ended June 30, 2006, net income was $17.3 million ($0.45 per common share, basic and fully diluted) as compared to a net loss of $3.2 million ($0.08 per common share, basic and fully diluted) for comparable period in 2005. For the three months ended June 30, 2006, net income was $21.2 million ($0.55 per common share, basic and fully diluted) as compared to a net loss of $11.3 million ($0.29 per common share, basic and fully diluted) for comparable period in 2005.

There are a number of factors contributing to changes in the results the largest of which is the gain on purchase and settlement of the exchangeable and development notes of $26.8 million.

Revenue / Revenue from research and development collaborations, licensing fees and milestone payments was $6.1 million for the second quarter and the first six months of 2006 as compared to nil for the second quarter of 2005 and $15.4 million for the first six months of 2005. Revenue in the first six months of 2005 was primarily a consequence of the recognition of deferred revenue and a one-time payment as a result of the termination of INEX's partnership with Enzon Pharmaceuticals. Revenue in the second quarter of 2006 arose from licensing and collaboration payments from partnerships with Hana and Alnylam.

On March 25, 2006, INEX signed an exclusive research collaboration agreement with Alnylam to evaluate systemic delivery of their RNAi therapeutics using the Company's liposomal technology. Under the collaboration agreement, Alnylam will pay a total of $0.64 million (US$0.55 million) in three equal payments as certain milestones are achieved. As at June 30, 2006, work under the collaboration agreement was two-thirds complete and two of the three collaboration payments or $0.42 million (US$0.37 million) had been paid to INEX and have been recognized as revenue in the quarter. Under the terms of the agreement, Alnylam also paid $0.15 million (US$0.13 million) for an option to execute a global license for specific RNAi therapeutic targets. This 90 day option expired on June 24, 2006 but was renewed for a further 90 days by a second payment of $0.14 million (US$0.13 million). Income for this option and its extension is being recognized on a straight-line basis therefore $0.2 million has been recorded as licensing fees and milestone payments in the second quarter of 2006. The license agreement would include upfront license fees, future milestone payments and royalties as the products are commercialized. Alnylam also has the right to expand the option to negotiate license terms for additional targets. On July 14, 2006, the Company signed an amendment to the research agreement with Alnylam. Under the amendment INEX received US$1.25 million by way of option payments including an option to take a broad exclusive license to INEX's technology and may receive up to an additional US$0.65 million to support certain expanded research programs.

On May 6, 2006, the Company signed a number of agreements with Hana including an agreement to issue worldwide licenses (the "License Agreement") for three of the Company's Targeted Chemotherapy products, Marqibo, INX-0125 and INX-0076. Under the License Agreement, Hana paid a non-refundable up-front cash payment of $1.7 million (US$1.5 million) and issued 1,118,568 Hana shares to INEX (together the "Up-front Payments"). The aggregate value of the Hana shares on May 6, 2006, based on a share price of $12.34 (US$11.15) was $13.8 million (US$12.5 million). Also on May 6, 2006, INEX signed an asset transfer agreement with Hana to transfer certain surplus laboratory equipment as part consideration for the Up-front Payments from Hana. The net book value of the assets transferred under this agreement was $0.2 million. Effective April 3, 2006, INEX also signed a Service Agreement under which Hana will reimburse INEX for future expenses and time spent in maintaining and transferring the technology and product expertise related to the three products.

In accordance with the Company's revenue recognition policy, $15.3 million of the Up-front Payments was deferred and is being amortized on a straight line basis from April 3, 2006 to December 31, 2006 when the Company expects to deliver substantially all of the services under the Service Agreement with Hana and $0.2 million has been allocated to the surplus laboratory equipment transferred to Hana giving a gain on disposal of nil. Therefore, of the $15.3 million portion of the Up-front Payments, $5.0 million has been recognized in the second quarter as licensing fees and milestone payments and the balance of $10.3 million has been deferred and will be recognized by December 31, 2006.


<<
Revenue is detailed in the following table:

Three months ended Six months ended
June 30, June 30, June 30, June 30,
(in millions Cdn$) 2006 2005 2006 2005
--------------------------------------------------

Research and development
collaborations
Enzon(1) $ - $ - $ - $ 1.3
Alnylam 0.4 - 0.4 -
Hana 0.5 - 0.5 -
--------------------------------------------------
Total research and
development
collaborations $ 0.9 $ - $ 0.9 $ 1.3

Licensing fees and
milestone payments
Enzon revenue
Amortization of up-front
payment(2) $ - $ - $ - $ 11.2
Milestones and
termination payment(1) - - - 2.7
Aradigm initial licensing
fee(3) - - - 0.2
Alnylam initial licensing
fee 0.2 - 0.2 -
Hana up-front payments 5.0 - 5.0 -
--------------------------------------------------
Total licensing fees and
milestone payments $ 5.2 $ - $ 5.2 $ 14.1

(1) In the first quarter of 2005 INEX received a product development
payment and milestone payment totalling $6.0 million (US$5.0 million)
as part of Enzon's termination of the strategic partnership. Of this
$6.0 million, $2.0 million was accrued at December 31, 2004 and
$4.0 million was recognized in the first quarter of 2005 including
$2.7 million in milestone and termination payments and $1.3 million
in research and development collaborations payments.

(2) Amortization of the up-front US$12.0 million payment received from
Enzon at the start of the strategic partnership in January 2004. As a
result of Enzon terminating the strategic partnership on March 16,
2005, the balance of previously deferred revenue was recognized as
revenue in the first quarter of 2005.

(3) Licensing fee received from Aradigm Corporation ("Aradigm") according
to the agreement dated December 8, 2004 under which Aradigm licensed
certain of the Company's sphingosomal technology.
>>


Revenue from the Hana and Alnylam partnerships in the second half of 2006 is expected to be approximately $12.0 million giving a total projected revenue for 2006 of approximately $18.1 million.

Expenses / Research and development / Research and development expenses decreased to $1.2 million for the second quarter of 2006 from $2.5 million in the same period in 2005 and to $2.5 million for the first half of 2006 from $6.4 million in the same period in 2006. This decrease relates primarily to reduced research and development personnel and reduced external costs for products in INEX's pipeline. Research and development salary expenses declined in the three months and six month period ending June 30, 2006 as compared to the same periods in 2005 as a result of a workforce reduction in June 2005. INEX's internal research and development staff was 18 at June 30, 2006 (total staff 28) as compared to 36 just prior to the June 2005 restructuring (total staff 57) and 18 at June 30, 2005 (total staff 30). Also contributing to the decrease in research and development costs is decreased external costs related to the Company's Targeted Chemotherapy platform for which spending was reduced after Enzon terminated the strategic partnership in the first quarter of 2005 and for which spending is now passed through to the Company's new Target Chemotherapy partner, Hana.

INX-0167 costs are expected to increase total research and development costs in the second half of the year and expected total research and development costs for 2006 are approximately $6.0 million.

General and administrative / General and administrative expenses fell to $1.0 million for the three months ended June 30, 2006 as compared to $1.3 million in the same period in 2005 and $2.2 million for the six months ended June 30, 2006 as compared to $2.7 million in the same period in 2005. The decline is largely attributable to reduced salaries and related costs resulting from the June 2005 workforce reductions. INEX also reduced lease and operating expenses through a sub-lease agreement for excess lab and office space effective October 1, 2005. Legal and consulting fees were, however, substantially higher in the three and six months ended June 30, 2006 as compared to the same periods in 2005 associated with the Hana and Alnylam partnerships and litigation with the former majority debt holder.

INEX expects to incur substantial professional fees as it looks to complete its corporate reorganization in the third quarter of 2006 and expects general and administrative costs for the year to approach $5.0 million.

Restructuring costs / Net restructuring costs in the three and six months period ended June 30, 2006 were nil as contrasted to $5.8 million in both the three and six month comparable periods. In June 2005 INEX completed a corporate restructuring reducing its workforce to a total of 30 employees (8 of which were interim employees).

Impairment of medical technology / The licensing of Targeted Chemotherapy technology to Hana and the purchase and settlement of the exchangeable and development notes which includes the assignment of a portion of at least some of the Hana milestones to the Former Noteholders, prompted management to review the fair value of INEX's medical technology. Potential net cash in-flows generated by the medical technology are several years away and are contingent upon the success of Hana's development of Marqibo. Management therefore decided to take a full impairment loss on medical technology and INEX recorded impairment of medical technology of $7.2 million in the quarter ended June 30, 2006. There is no comparative figure for this expense item.

Amortization / Amortization expense was $0.2 million for the second quarter of 2006 and $0.6 million for the comparable period in 2005. Current year to date amortization expense is $0.6 million as compared to $1.2 million for the six months ended June 30, 2005. The decrease is largely due to minimal amortization expense on leasehold improvements in 2006 due to the $1.5 million impairment loss recorded in the second quarter of 2005, the sale of laboratory equipment in the fourth quarter of 2005 and a provincial sales tax refund of $0.2 million that was confirmed in the second quarter of 2006 and is related to property and equipment that had already been fully amortized.

Total amortization for 2006 is expected to be approximately $1.0 million.

Other Income/Losses / Interest income / Interest income was $0.11 million for the second quarter and $0.21 million for the first six months of 2006 as compared to $0.12 million for the second quarter and $0.26 for the first six months of 2005. The decrease is a result of a decrease in the average cash and cash equivalents held during the 2006 periods as compared to the 2005 periods, somewhat offset by higher average interest rates in 2006. The Company anticipates that in future periods interest income will continue to fluctuate in relation to cash balances and interest yields (see Risks and uncertainties).

Interest on exchangeable and development notes / Interest expense on the US dollar denominated exchangeable and development notes (the "Notes") was $0.9 million for the three months and $1.9 million for the six months ended June 30, 2006 as compared to $1.0 million and $2.0 million for the comparable periods in 2005. On June 20, 2006, INEX signed a purchase and settlement agreement with the holders of the Notes (the "Purchase and Settlement"). There will be no interest charged or recorded for accounting purposes on the Notes after their purchase and settlement on June 20, 2006.

Gain on purchase and settlement of exchangeable and development notes / On June 20, 2006 INEX signed a purchase and settlement agreement with the Former Noteholders and recorded a gain on settlement of $26.8 million. There is no comparative amount for this item.

Going forward, any milestone payments received from Hana, will be recorded in INEX's Statement of Operations as licensing fees and milestone payment revenue with an equal and opposite adjustment to gain on purchase and settlement of exchangeable and development notes. The net effect of these adjustments on net income or loss will be nil.

Foreign exchange and other gains (losses) / Foreign exchange and other gains (losses) showed gains of $1.7 million for the second quarter and gains of $1.6 million for the first six months of 2006 as compared to losses of $0.3  million for the second quarter and losses of $0.4 for the first six months of 2005. Foreign exchange and other gains (losses) are largely the result of foreign exchange gains and losses on the US dollar denominated exchangeable and development notes. The Canada/US dollar exchange rate is expected to continue to fluctuate in future periods (see Risks and uncertainties).

Investment in Protiva Biotherapeutics Inc. ("Protiva") / In the third quarter of 2005, Protiva issued new share capital thereby reducing INEX's ownership percentage from 34% to 7% such that INEX no longer has significant influence over Protiva, and now applies the cost method of accounting to this investment.

Loss on disposal of Hana Biosciences, Inc. shares / On June 20, 2006, as a part of the consideration for the purchase of the Notes, INEX transferred 1,118,568 Hana shares with a value at that time of $10.7 million (US$9.6 million) to the Former Noteholders. The 1,118,568 Hana shares were first recorded on May 6, 2006, the date they were issued, at their then trading price of $12.38 (US$11.15) giving an aggregate value of $13.8 million (US$12.5  million). The loss in value of the Hana shares of $3.1 million has been recorded in the second quarter of 2006 as Loss in value of Hana shares.

Income taxes / In the first quarter of 2005 the Company accrued $0.5 million (US$0.4 million) of income taxes payable relating to a portion of the termination payment received from Enzon, which may give rise to a tax liability. The $0.001 million income tax expense in second quarter of 2006 represents an adjustment to the US income tax provision now that the Company has finalized and filed its 2004 and 2005 US income tax returns.

Capital Expenditures / Capital expenditures were $0.06 million in the second quarter and $0.08 million in the first half of 2006 and $0.009 million and $0.05 million for the comparable periods in 2005. Of the capital additions in the first half of 2006, $0.11 million were funded by capital leases.

RISKS AND UNCERTAINTIES

INEX's funding needs and those of Tekmira if the spin-out is completed may vary depending on a number of factors including:


<<
- revenues earned from the Service Agreement with Hana
- the cost of the corporate reorganization that will see all
transferable assets and liabilities spun out into Tekmira
- the extent to which the Company continues development or can extract
significant value from its technologies
- INEX's ability to attract corporate partners, and their
effectiveness in carrying out the development and ultimate
commercialization of its product candidates
- the decisions, and the timing of decisions, made by health
regulatory agencies regarding INEX's technology and products
- the Company's decisions to in-license or acquire additional products
for development
- competing technological and market developments
- prosecuting and enforcing patent claims and other intellectual
property rights
>>


INEX's risks and uncertainties are discussed in detail in the "Management's Discussion and Analysis of Financial Operations" portion of the Company's 2005 Annual Report and in its Annual Information Form dated March 29, 2006. INEX's 2005 Annual Report and Annual Information Form is available at www.sedar.com.


<<
FINANCIALS

Consolidated Balance Sheets

(Expressed in Canadian Dollars) June 30 December 31
2006 2005
--------------------------------------------------
unaudited
ASSETS
Current assets
Cash and cash equivalents $ 6,379,408 $ 12,173,022
Accounts receivable 1,424,850 301,922
Prepaid expenses and other assets 179,576 209,160
--------------------------------------------------
Total current assets 7,983,834 12,684,104


Property and equipment 768,274 1,107,170
Medical technology - 7,688,820
--------------------------------------------------
$ 8,752,108 $ 21,480,094
--------------------------------------------------
--------------------------------------------------

LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Current liabilities
Accounts payable and accrued liabilities $ 1,339,282 $ 1,933,402
Income tax payable 432,025 433,799
Current portion of obligations under
capital leases 93,186 57,594
Current portion of deferred lease
inducements 140,735 140,735
Deferred revenue 10,435,831 -
--------------------------------------------------
Total current liabilities 12,441,059 2,565,530

Obligations under capital leases 125,108 99,302
Exchangeable and Development Notes - 40,158,926
Deferred lease inducements 64,409 134,777
--------------------------------------------------
Total liabilities 12,630,576 42,958,535

Shareholders' deficiency:

Common share capital:
June 30, 2006 - 38,566,788 180,237,917 180,237,917
December 31, 2005 - 38,566,788
Additional paid-in capital 14,938,244 20,569,880
Deficit (199,054,629) (222,286,238)
--------------------------------------------------
Total shareholders' deficiency (3,878,468) (21,478,441)
--------------------------------------------------
$ 8,752,108 $ 21,480,094
--------------------------------------------------
--------------------------------------------------



Consolidated Statements of Operations and Deficit

(Expressed in Canadian Dollars)

Three months ended Six months ended
June 30 June 30 June 30 June 30
2006 2005 2006 2005
--------------------------------------------------
unaudited unaudited unaudited unaudited
Revenue
Research and
development
collabora-
tions $ 940,033 $ - $ 940,033 $ 1,299,398
Licensing fees
and milestone
payments 5,129,431 - 5,140,787 14,136,818
--------------------------------------------------
6,069,464 - 6,080,820 15,436,216
--------------------------------------------------

Expenses
Research and
development 1,179,617 2,516,861 2,451,526 6,428,865
General and
administrative 1,026,369 1,290,695 2,171,319 2,720,967
Restructuring
costs - 5,823,634 - 5,823,634
Impairment of
medical
technology 7,210,515 - 7,210,515 -
Amortization 187,089 598,523 620,472 1,195,595
--------------------------------------------------
9,603,590 10,229,713 12,453,832 16,169,061
--------------------------------------------------

Income (Loss)
from operations (3,534,126) (10,229,713) (6,373,012) (732,845)

Interest income 108,777 121,153 205,137 260,458
Interest on
exchangeable
and development
notes (881,194) (999,916) (1,872,729) (2,022,411)
Gain on purchase
and settlement
of exchangeable
and development
notes 26,844,179 - 26,844,179 -
Foreign exchange
and other gains
(losses) 1,725,414 (320,431) 1,554,515 (411,434)
Dilution gain
from Protiva
Biotherapeutics
Inc. - 192,176 - 852,672
Equity in loss
of Protiva
Biotherapeutics
Inc. - (30,914) - (691,410)
Loss on disposal
of Hana
Biosciences,
Inc. shares (3,069,049) - (3,069,049) -
--------------------------------------------------
Income (Loss)
before income
taxes 21,194,001 (11,267,645) 17,289,041 (2,744,970)

Income taxes 806 - 806 451,000
--------------------------------------------------
Net income
(loss) $ 21,193,195 $ (11,267,645) $ 17,288,235 $ (3,195,970)

Deficit,
Beginning of
period (226,191,198) (204,854,424) (222,286,238) (212,926,099)

Discount on
exchangeable
and development
notes 5,943,374 - 5,943,374 -

--------------------------------------------------
Deficit, End
of period $(199,054,629) $(216,122,069) $(199,054,629) $(216,122,069)
--------------------------------------------------
--------------------------------------------------

Weighted
average number
of common
shares
Basic 38,566,788 38,566,788 38,566,788 38,566,788
Diluted 38,771,614 38,566,788 38,580,453 38,566,788

Income (Loss)
per common
share
Basic $ 0.55 $ (0.29) $ 0.45 $ (0.08)
Diluted $ 0.55 $ (0.29) $ 0.45 $ (0.08)



Consolidated Statements of Cash Flow

(Expressed in Canadian Dollars)

Three months ended Six months ended
June 30 June 30 June 30 June 30
2006 2005 2006 2005
--------------------------------------------------
unaudited unaudited unaudited unaudited

OPERATIONS
Income (Loss)
for the
period $ 21,193,195 $ (11,267,645) $ 17,288,235 $ (3,195,970)
Items not
involving cash:
Amortization
of property
and equipment (51,376) 353,038 142,176 710,279
Impairment loss
on property and
equipment - 1,528,064 - 1,528,064
Amortization of
medical
technology 238,465 242,565 478,305 482,396
Impairment loss
on medical
technology 7,210,515 7,210,515
Amortization of
deferred lease
inducements (35,184) (34,797) (70,368) (69,594)
Amortization of
other long-term
assets - 1,458 - 800,492
In kind
contribution
of capital
assets - 61,043 - 61,043
Interest on
exchangeable
and develop-
ment notes 881,194 999,916 1,872,729 2,022,411
Unrealized
foreign
exchange gain
(loss) on
exchangeable
and develop-
ment notes (1,838,930) 538,775 (1,659,484) 793,688
Gain on
purchase and
settlement of
exchangeable
and develop-
ment notes (26,844,179) (26,844,179)
Dilution gain
from Protiva
Biotherapeutics
Inc. - (192,176) - (852,672)
Equity in loss
of Protiva
Biotherapeutics
Inc. - 30,914 - 691,410
Loss on
disposal of Hana
Biosciences,
Inc. shares 3,069,049 - 3,069,049 -
Stock-based
compensation
expense 82,002 102,750 311,738 247,743
Gain from sale
of property
and equipment - - (10,948) -
Change in
deferred
revenue (3,199,800) - (3,199,800) (11,155,715)
Net change in
non-cash
working
capital (345,835) 3,910,210 (1,460,255) 849,210
--------------------------------------------------
359,116 (3,725,885) (2,872,287) (7,087,215)
--------------------------------------------------

INVESTMENTS
Proceeds from
sale of
property and
equipment - - 16,492 -
Acquisition of
property and
equipment (58,002) (8,554) (76,995) (52,281)
--------------------------------------------------
(58,002) (8,554) (60,503) (52,281)
--------------------------------------------------

FINANCING
Repayment of
long-term debt,
net of security
deposit - (205,050) - (407,552)
Repayment of
obligations
under capital
leases (22,203) (36,841) (70,324) (79,691)
Repayment of
exchangeable
and develop-
ment notes (2,790,500) - (2,790,500) -
--------------------------------------------------
(2,812,703) (241,891) (2,860,824) (487,243)
--------------------------------------------------

Increase
(decrease) in
cash and cash
equivalents (2,511,589) (3,976,330) (5,793,614) (7,626,739)

Cash and cash
equivalents,
beginning of
period 8,890,997 26,395,367 12,173,022 30,045,776
--------------------------------------------------
Cash and cash
equivalents,
end of
period $ 6,379,408 $ 22,419,037 $ 6,379,408 $ 22,419,037
--------------------------------------------------
--------------------------------------------------
>>


About INEX

INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about INEX and this news release can be found at www.inexpharm.com.

Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, INEX's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market INEX's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

INEX's common shares are traded on the Toronto Stock Exchange under the

trading symbol "IEX".

SOURCE: Inex Pharmaceuticals Corporation

Contacts for Inex Pharmaceuticals Corporation: Investors: Ian Mortimer, Vice President, Finance and Chief Financial Officer, Phone: (604) 419-3200, Email: info@inexpharm.com, Website: www.inexpharm.com; Media: Karen Cook Boas, James Hoggan & Associates Inc., Phone: (604) 739-7500, Email: kcook@hoggan.com

Copyright (C) 2006 CNW Group. All rights reserved.

Genau diese Marke ist ein wichtiger Widerstand. Wird der nachhaltig geknackt, kann es sehr schnell wieder auf und über 10$ laufen.

.

RT 8,15USD

Kommt nun noch ein Käfer, muss er wohl zum Tageshoch kaufen. Ist ein tolles Zeichen, wenn sie täglich 2-3% steigt und auf Tageshoch schließt! Chart sieht auch suuuuper aus!

.

Schritt für Schritt gen Norden- so ist's schön.

Die Richtung stimmt. Solider Anstieg bei ordentlichem Volumen. Heute in USA über 240k gehandelte Aktien.

in hana. Bin leider schon bei 8,20 rein habe dann aber verbilligt. 80 cent fehlen noch auf null und dann geht`s hoffenlich in`s Plus. Jeden Tag ein kleines Stück höher ist gesünder als große Ausschläge rauf und runter. Hoffentlich hält der Trend der letzten Tage und auch der positive Newsflow an.
grüße vom Waleshark.

Ich hatte Hana früher auch schon einmal. Glücklicherweise hatte ich einen Tag bevor sie damals entdeckt und empfohlen wurde über Suchmaschinen die Andeutungen richtig interpretiert, war als Erster auf das Untenrehmen gestoßen und konnte ca. 100% Gewinn  realisieren, war dann aber viel zu früh raus.

Inzwischen bin ich aber von der Vorstandsetage mit ihrer vielen Erfahrung und der Pipeline von Hana derart überzeugt, dass ich mir sicher bin, dann die Aktie in den nächsten Jahren (!!!) noch viel Freude bereiten wird.

Hana Biosciences Announces Conference Call on Second Quarter 2006 Financial Results and Business Update
8/3/2006      

SOUTH SAN FRANCISCO, Calif., Aug 03, 2006 (BUSINESS WIRE) --
Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, will announce its 2006 second quarter results on Monday, August 14th, prior to the open of the financial markets.

Following the announcement, Hana Biosciences' management will host a live webcast to include a discussion of earnings and a business update at 5:30am PDT, 8:30am EDT. Those interested in hearing management's discussion may join the call by dialing (866) 585-6398 in the US/Canada. International participants may access the call by dialing (416) 849-9626. Participants may also access a live webcast of the conference call Hana's website at www.hanabiosciences.com.

An audio replay will be available until August 21st following the call by dialing (888) 566-0813 US/Canada and (402) 220-2507 for International participants. Enter #4111557 when prompted for the playback access code. The webcast will be available via the company's website until August 28th.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the three months ended March 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 investor.relations@hanabiosciences.com fax: 650-588-2787

Copyright Business Wire 2006

Klasse!

6,43€. 6,45€ im Ask.

Auch in Frankfurt und München auf Tageshoch. Hat sich ein sehr schöner Trend gebildet. Nun wird sie wie von allein laufen in den kommenden Wochen.

;-)

In der letzten Ausgage von "der Aktionär" ist ein sehr positiver Bericht und Interview mit dem Vorstandschef Mark Ahn. Trägt vielleicht ein bißchen zur positiven Entwicklung bei. Grüße vom Waleshark.  

Der gesamte Biotech-Sektor ist heute schwach, sodass es völlig normal ist, dass Hana mit dem Markt etwas fällt.  

Sehr geringes Volumen heute. Ist ein gutes Zeichen: Anstieg in den letzten Tagen bei hohem Volumen, Konsolidierung bei geringem Volumen. Ist die Basis für einen langfristigen Aufwärtstrend!;-)

Wochengewinn innerhalb so kurzer Zeit futsch ist, ist das für mich keine gesunde Konsolidierung sondern ganz einfach ein herber Rückschlag. Wer etwas schönredet belügt sich selber. Sicher bn ich jetzt enttäuscht vom Kursverlauf, denn ich hatte gehofft wie gehen mit 6,4xx in`s Wochenende. Volumen hin Volumen her, Fakt ist doch ein krasses absacken bis über 8%, jetzt immer noch 6%. Ich habe jedenfalls unter 5,83 noch ein Limit gesetzt um noch mal etwas zu verbilligen. Könnte nächste Woche durchaus noch weiter runtergehen. Ich glaube wie Du an den Wert aber Hana ist nunmal extrem volatil. Außerdem fahre ich am Sonntagmittag in den Urlaub und lasse einfach laufen. Mal sehen wie`s ausschaut, wenn ich in 14 tagen wiederkomme. Bis dahin viel Glück.
Grüße vom Waleshark.

Wenn du mit ana nur kurzfristig denkst, ist es für dich natürlich nicht so toll.

Wer an die Story glaubt (so wie ich), den wird es in einigen Jahren kaum jucken, ob man zu 5,80€ oder zu 6,50€ eingestiegen ist. So nutzt man solche Chancen eben zum Nachkaufen. Wenn man sich den Chart anschaut, erkennt man auch schön, dass in allen Aufwärtsperioden immerwieder einzelne Tage vorkamen, an denen es mehrere Prozente abwärts ging. Völlig normal und ok. Wenn du mit sowas nicht leben kannst und willst, solltest du dir besser DAX-Werte ins Depot legen!;-)

Waren wohl die Meisten schon im Wochenende!*lach*

Wie gehts hier weiter?

7,40USD scheint SK zu sein.

@Nukem: Du, Kursziele anzugeben ist nicht meine Sache. Alles schwer abzuschätzen.

Aber wie ich schon mehrfach geschrieben habe, sehe ich das sehr langfristig (mehrere Jahre). Der gute Newsflow sollte anhalten und da man die Zulassung von Zensana bei der FDA inzwischen beantragt hat, rechne ich hier noch im Herbst mit der Zulassung. Sollten weitere Blockbuster, die sich momentan in den verschiedenen klinischen Phasen befinden (Pipeline weiter oben im Thread), wird Hana in neue Regionen (kurstechnisch und umsatzmäßig) vordringen. Also persönlich bin ich davon überzeugt, dass man sein Geld auf Sicht von ein paar Jahren hier vervielfachen können wird.

Macht ja nix. ;-)Kannst du ja ruhig haben. Mir wäre es aber zu langweilig. Ich brauche den Nervenkitzel. Freue mich auch schon auf die kommende Woche, weil dann German Brokers abgehen wird!;-)

Schönes Wochenende!

Die Voraussetzungen für einen nachhaltigen Aufschwung sieht Ahn als gegeben: Der Antrag auf Zulassung des Medikamentes Zensana wurde fristgerecht zum 30. Juni 2006 bei den US-Behörden eingereicht. Mit der Zulassung, für das Mittel, das gegen Übelkeit und Erbrechen bei Chemotherapie eingesetzt werden soll, rechnet Hana im ersten Halbjahr 2007. Bis Ende dieses Jahres will Hana die Erlaubnis von der US-Gesundheitsbehörde FDA erhalten, mit den Phase-III-Tests mit dem potenziellen Blutkrebsmittel Marqibo zu beginnen. Den experimentellen Wirkstoff hatte Hana erst im Mai 2006 von der Firma Inex einlizenziert. Auch bei Talotrexin, das unter dem Namen Talvesta verkauft werden soll, verläuft die Entwicklung planmäßig. Zum Ende dieses Jahres will Hana Daten aus einer laufenden Studie der Phase II präsentieren. In dieser wird Talvesta auf seine Eignung zur Behandlung von Lungenkrebs geprüft. Am Geld wird die erfolgreiche Fortentwicklung der Produktkandidaten nicht scheitern: Nach mehreren erfolgreichen Kapitalmaßnahmen ist die Hana-Kasse mit rund 50 Millionen Dollar gut gefüllt.
Schlechtes Timing

Die Kaufempfehlung im Juni hat sich im Nachhinein als zu früh erwiesen, wie die jüngste Talfahrt bewiesen hat. Dies ändert jedoch nichts an den langfristig sehr guten Perspektiven für das Unternehmen. Risikobereite Anleger nutzen deshalb das aktuelle Niveau zum Aufbau einer kleinen Position.

Erschienen in DER AKTIONÄR Ausgabe 32/2006.

Wie geschrieben war es am Freitag nur eine kleine, gesunde Konsolidierung, damit der langfristige Aufwärtstrend auf solideren Füßen steht.

Schöner Doppelboden wurde gebildet und im Moment geht es mächtig hoch bei steigenden Umsätzen in USA!!:-)

Schluss fast auf Tageshoch. Damit könnte die Bodenbildung abgeschlossen sein und wir bilden ein schönes "W"!

"In the second quarter of 2006, we achieved a significant number of clinical, regulatory and business development milestones," said Mark J. Ahn, Ph.D., President and CEO of Hana. "We are pleased to have completed and submitted our NDA for Zensana(TM) as we believe this product has the potential to offer a convenient and attractive alternative to those patients suffering from chemotherapy, radiotherapy, and post-operative induced nausea and vomiting. In addition we doubled the size of our product pipeline during the quarter as a result of our transaction with Inex, while advancing several clinical-stage programs on schedule with corporate timelines."

A reconciliation(2) between non-GAAP and GAAP earnings per share for the second quarters of 2006 and 2005 is provided in the following table:

--------------------------------------------------            Reported      Employee         Costs        Non-GAAP           GAAP Basic      Stock         Associated    Basic and           and Diluted   Compensation    with Inex      Diluted              EPS          Expense       Acquisition     EPS--------------------------------------------------Q2 2006     ($0.81)        $0.09           $0.48         ($0.26)--------------------------------------------------Q2 2005     ($0.13)        $0.00           $0.00         ($0.13)--------------------------------------------------YTD 2006    ($1.00)        $0.11           $0.50         ($0.41)--------------------------------------------------YTD 2005    ($0.29)        $0.00           $0.00         ($0.29)--------------------------------------------------
Note: Amounts may not sum due to rounding.

Key Achievements in Second Quarter 2006

-- Announced the submission of a New Drug Application (NDA) for Zensana (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy and post-operative induced nausea and vomiting. If approved, Hana targets commercial launch of Zensana in the United States in the first half of 2007.

-- Initiated a multicenter, multinational Phase II clinical trial with Talvesta(TM) (talotrexin) in relapsed or refractory non-small cell lung cancer (NSCLC).

-- Completed licensing of three additional targeted cancer drug candidates from Inex Pharmaceuticals.

-- Presented Phase I clinical results in solid tumors and NSCLC with Talvesta at the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting.

-- Presented pivotal trials confirming Zensana(TM) (ondansetron HCl) Oral Spray 8 mg dose is statistically bioequivalent to the current commercially available 8 mg ondansetron tablet at the ASCO Annual Meeting.

-- Presented new survey results at the ASCO Annual Meeting which indicated medical oncologists, radiation oncologists and oncology nurses surveyed believe Zensana may be an attractive formulation for patients with chemotherapy and radiotherapy induced nausea and vomiting.

-- Announced that the FDA granted orphan drug designation for Talvesta in patients with acute lymphoblastic leukemia (ALL).

-- Announced that the FDA granted orphan drug designation for Ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors.

-- Announced that Hana joined the Russell 3000(R) Index and the Russell Microcap(TM) Index on June 30, 2006.

-- On April 17, 2006 Hana's common shares began trading on the NASDAQ Global Market (formerly the NASDAQ National Market) under the symbol HNAB.

Hana Biosciences' management will host a live webcast to include a discussion of earnings and a business update at 5:30 am PDT, 8:30 am EDT. Those interested in hearing management's discussion may join the call by dialing (866) 585-6398 in the US/Canada. International participants may access the call by dialing (416) 849-9626. Participants may also access a live webcast of the conference call on Hana's website at www.hanabiosciences.com.

An audio replay will be available until August 21, 2006 following the call by dialing (888) 566-0813 US/Canada and (402) 220-2507 for International participants. Enter #4111557 when prompted for the playback access code. The webcast will be available via the company's website until August 28, 2006.

Reconciliation of GAAP to Non-GAAP Net Loss:

GAAP refers to generally accepted accounting principles in the United States of America. Hana's non-GAAP net loss and loss per share excludes the impact of the one-time upfront fees paid to Inex Pharmaceuticals Corp. and transaction fees paid as part of its acquisition and stock option expense related to implementation of FAS 123R. We are reporting non-GAAP results in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP. The Company provides these non-GAAP numbers to facilitate a comparison of our business from period to period and to allow investors to analyze our business results using the same measures our management uses to evaluate our operating performance. We encourage investors to carefully consider our results under GAAP, as well as our non-GAAP reconciliation between these presentations to more fully understand our business.

(1) The company adopted Statement of Financial Accounting Standards No. 123R (or FAS 123R) on a modified prospective basis beginning January 1, 2006. As a result, no employee stock-based compensation expense using FAS 123R has been recognized in GAAP-reported amounts in any prior period.

(2) Hana's non-GAAP net loss and non-GAAP loss per share excludes the impact of the one-time upfront fees paid to Inex Pharmaceuticals and transaction fees paid as part of its acquisition of three product candidates. The differences in non-GAAP and GAAP numbers are reconciled in the accompanying tables.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's most recently filed Form 10-K and Form 10-Q. Hana assumes no obligation to update these statements, except as required by law.

                       HANA BIOSCIENCES, INC.                     (A DEVELOPMENT STAGE COMPANY)                       CONDENSED BALANCE SHEETS                                            June 30,    December 31,                                              2006          2005                                          ------------- --------------ASSETS                                     (Unaudited)Current assets:Cash and cash equivalents                 $ 44,266,298  $  17,082,521Short term investments                       2,332,051        472,000Prepaid expenses and other current assets       69,744         74,729                                          ------------- --------------   Total current assets                     46,668,093     17,629,250Property and equipment, net                    323,899         76,496Other assets                                        --         20,453 Restricted cash                               125,166             --                                          ------------- -------------- Total assets                             $ 47,117,158  $  17,726,199                                          ============= ==============LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable                          $  1,091,750  $     671,491Accrued expenses                             2,742,488        865,135                                          ------------- -------------- Total liabilities                           3,834,238      1,536,626                                          ------------- --------------Commitments and contingencies Stockholders' equity:  Common stock to be issued                    185,841             --  Common stock; $0.001 par value  100,000,000 shares authorized;   28,742,784 and 22,348,655 shares   issued and outstanding at June 30,   2006 and December 31, 2005,   respectively                                 28,743         22,349Additional paid-in capital                  85,372,186     34,400,345Accumulated other comprehensive loss           (96,000)      (164,000)Deficit accumulated during the development stage                         (42,207,850)   (18,069,121)                                          ------------- --------------   Total stockholders' equity               43,282,920     16,189,573                                          ------------- --------------Total liabilities and stockholders' equity                                   $ 47,117,158  $  17,726,199                                          ============= ==============                        HANA BIOSCIENCES, INC.                     (A DEVELOPMENT STAGE COMPANY)       CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS                              (Unaudited)                                              Three Months Ended                                                    June 30,                                          ----------------------------                                              2006           2005                                          ------------- --------------Operating expenses:General and administrative                $  2,576,308  $     963,270Research and development                    18,368,374      1,150,447                                          ------------- --------------Total operating expenses                    20,944,682      2,113,717Loss from operations                       (20,944,682)    (2,113,717)                                          ------------- --------------Other income (expense):Interest income, net                           249,426         30,495Other expense, net                              (8,800)        (2,633)                                          ------------- -------------- Total other income (expense)                  240,626         27,862                                          ------------- --------------Net loss                                  $(20,704,056) $  (2,085,855)                                          ============= ==============Net loss per share, basic and diluted                                  $      (0.81) $       (0.13)                                          ============= ==============Shares used in computing net loss per share, basic and diluted                                    25,640,398     15,726,776Comprehensive loss:Net loss                                  $(20,704,056) $  (2,085,855)Unrealized gain (loss)                        (156,000)             -                                          ------------- --------------Comprehensive loss                        $(20,860,056) $ (2,085,855)                                          ============= ==============                                                          Cumulative                                                         Period from                                                         December 6,                                                            2002                                                         (date of                                Six Months Ended         inception)                                    June 30,                to                           ---------------------------    June 30,                               2006          2005           2006                           ------------- ------------- ---------------Operating expenses:General and administrative $  3,560,283  $  1,670,483  $   10,393,865Research and development     20,946,506     2,872,172      32,360,602                           ------------- ------------- ---------------Total operating expenses     24,506,789     4,542,655      42,754,467Loss from operations        (24,506,789)   (4,542,655)    (42,754,467)                           ------------- ------------- ---------------Other income (expense):Interest income, net            384,752        50,062         583,533Other expense, net              (16,692)      (10,137)        (36,916)                           ------------- ------------- --------------- Total other income  (expense)                     368,060        39,925         546,617                           ------------- ------------- ---------------Net loss                  $ (24,138,729) $ (4,502,730) $  (42,207,850)                           ============= ============= ===============Net loss per share, basic and diluted                      (1.00) $      (0.29)                           ============= =============Shares used in computing net loss per share, basic and diluted                 24,037,103    15,402,248Comprehensive loss:Net loss                   $(24,138,729) $ (4,502,730)Unrealized gain (loss)           68,000             -                           ------------- -------------Comprehensive loss         $(24,070,729) $ (4,502,730)                           ============= =============
SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 (Investor & Media) Fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006


Quelle: www.stockhouse.com/news/news.asp?newsid=3844331&tick=HNAB

.

.

Sieht so aus, als würde sich nun ein "W" wie wunderschön bilden! Damit stimmt die Richtung wieder!:-)

.

.

D 5,76€
USA $7.34

.

Hohes Handelsvolumen!

Das andere wäre ja der Schlusskurs vom 16.September!*lach*

Schon über 130000 gehandelte Aktien. Das gabs lange nicht mehr bei Hana. Gleich nachbörsliche News? Ich vermute es mal...

SK $7.29.

Habe das Gefühl, dass gleich noch News kommen.

.

"Adults with relapsed ALL have very few options for effective therapy. Several trials in lymphoproliferative malignancies including non-Hodgkin's lymphoma (NHL) and two Phase I trials in ALL have shown promising potential for Marqibo to improve clinical outcomes. This preliminary data supports moving this drug into pivotal trials," commented Dr. Greg Berk, Senior Vice President and Chief Medical Officer of Hana Biosciences.

Previous positive interim data from the Phase I clinical trial evaluating Marqibo in combination with dexamethasone in relapsed or refractory ALL was presented at the American Society of Hematology annual meeting in December 2004. The complete Phase I data is expected to be presented in the fourth quarter of 2006.

About Marqibo(R)

Marqibo utilizes vincristine encapsulated in a rigid, lipid bilayer of sphingomyelin. Vincristine is an FDA approved, standard chemotherapeutic used in most lymphoma and ALL regimens. It is a cell-cycle specific agent whose activity is dependent on the duration of drug exposure. The sphingosome encapsulated technology employed by Marqibo results in a liposome which is more rigid than conventional liposomes. Consequently, with Marqibo, the active vincristine leaks out of the liposome slowly and drug levels are maintained for prolonged periods of time. This improved pharmacokinetic profile of Marqibo, which mimics a continuous vincristine infusion, may result in greater activity in rapidly dividing cancers.

The anticipated activity associated with vincristine has traditionally been limited by its short half-life, and its inability to be dose escalated beyond 2mg due to neurotoxicity. In Phase I and II studies, Marqibo has shown to have a significantly longer half-life and patients have been able to tolerate doses which are 100 percent greater than conventional vincristine. These trials provide the rationale for utilizing this technology in lymphoproliferative diseases, such as ALL, Hodgkin's and non-Hodgkin's lymphoma.

This sphingosome encapsulated technology was discovered at the University of British Columbia and subsequently developed by Inex Pharmaceuticals Corporation. In May 2006, Hana Biosciences licensed from Inex the worldwide rights to three drug candidates utilizing this technology, including Marqibo.

About Acute Lymphoblastic Leukemia (ALL)

Approximately 4,000 cases of ALL are diagnosed annually in the United States. While cure rates for childhood ALL have steadily improved to nearly 90 percent, adult ALL reported cure rates seldom exceed 40 percent. The poorer outcome in adult ALL has been attributed to an increased frequency of high-risk leukemia with greater resistance, poorer tolerance of and compliance with treatment, reluctance to accept toxic effects, and less effective treatment regimens as compared with childhood ALL. Currently, there are no approved agents for ALL salvage, nor is there a consensus on the most appropriate regimen in the relapse setting. Ongoing efforts are needed to investigate agents for this indication, as well as incorporate active agents, once identified, into frontline therapy.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

About Inex Pharmaceuticals Corporation

Inex Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Since 1996, INEX common shares have been trading on the Toronto Stock Exchange under the symbol "IEX". Additional information on Inex Pharmaceuticals can be found at www.inexpharm.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to Marqibo and its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, including Marqibo, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 (Investor & Media Contacts) Fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006

Auch das Volumen mit ca. 90000 Aktien wieder "normal". Der Aufwärtstrend ist weiterhin intakt.

Zensana(TM) (ondansetron HCI) Oral Spray is the first 5-HT3 antagonist to deliver ondansetron, a standard antiemetic therapy, in a convenient, micromist oral spray to patients suffering from chemotherapy, radiation, and post-operative associated nausea and vomiting. Based on clinical trial data presented June 3, 2006 at the American Society of Clinical Oncology Conference, Hana believes Zensana is statistically bioequivalent to ondansetron tablets with faster initial delivery. Ondansetron, a selective blocking agent of the hormone serotonin, is an FDA-approved active ingredient that is widely used in tablet form to prevent chemotherapy, radiation, and post-operative associated nausea and vomiting. Many patients requiring antiemetic therapy experience dysphagia, a discomfort or difficulty swallowing tablets, due to mouth and throat sores, inflammation, or dry mouth. Hana believes that the convenience of drug delivery via an oral spray may offer an attractive alternative to tablets and other forms of ondansetron. Hana holds the exclusive rights to market the novel oral spray formulation in the U.S. and Canada pursuant to a license from NovaDel Pharma, Inc. (AMEX:NVD).

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that Hana's NDA for Zensana will be approved by the FDA. Further, even if the NDA for Zensana is approved, Hana efforts to commercialize Zensana may not be successful, which would have a material adverse effect on its financial condition and business prospects. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's other product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Investor & Media: Remy Bernarda, 650-228-2769 fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006

In the June 20, 2006 announcement, INEX reported that it had signed a definitive note purchase and settlement agreement with all of the holders of certain convertible promissory notes issued by a wholly-owned subsidiary of INEX and guaranteed by INEX. The notes were owned by institutional investors.

Future payments to the former noteholders are contingent on INEX receiving milestone or royalty payments from Hana and other consideration received by INEX should it complete the corporate reorganization that will be voted upon by INEX shareholders September 20, 2006. The form of corporate reorganization contemplated in the note purchase agreement would transfer all of INEX's pharmaceutical assets to its subsidiary, Tekmira Pharmaceuticals Corporation.

All of the shares in Tekmira would be distributed pro rata to INEX shareholders allowing INEX to raise additional capital in connection with the acquisition of a new business and this capital would be transferred to the noteholders. If INEX does not receive any future proceeds from Hana or from the contemplated corporate reorganization then it will not owe the noteholders any additional consideration or payments. No interest will accrue on the amount owed to the noteholders.

About INEX

INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about INEX and this news release can be found at www.inexpharm.com.

Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Inex's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Inex's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

INEX's common shares are traded on the Toronto Stock Exchange under the trading symbol "IEX".

SOURCE: Inex Pharmaceuticals Corporation

Inex Pharmaceuticals Corporation: Investors: Ian Mortimer, Vice President, Finance and Chief Financial Officer, Phone: (604) 419-3200, Email: info@inexpharm.com, Website: www.inexpharm.com; Media: Don Bradley, James Hoggan & Associates Inc., Phone: (604) 739-7500, Email: dbradley@hoggan.com

Copyright (C) 2006 CNW Group. All rights reserved.

Die Tragweite dieser tollen News wird sich in den nächsten Wochen sicherlich noch deutlicher im Kurs niederschlagen!

Und das bei überdurchschnittlich hohem Volumen.

Das gab es schon seit Wochen nicht mehr, wenn ich mich recht entsinne.

Hana Biosciences to Present at the NewsMakers in the Biotech Industry Conference
8/31/2006      

SOUTH SAN FRANCISCO, Calif., Aug 31, 2006 (BUSINESS WIRE) --
Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Fred Vitale, Vice President & Chief Business Officer, will present a company update at the NewsMakers in the Biotech Industry Conference on Thursday, September 7th at 1:30 p.m. EDT in Room 404/405 at the Millennium Broadway Hotel in New York, NY.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to Marqibo and its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, including Marqibo, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.

SOURCE: Hana Biosciences, Inc.

Hana Biosciences, Inc. Remy Bernarda, 650-228-2769 fax: 650-588-2787 investor.relations@hanabiosciences.com

Copyright Business Wire 2006

Es ist schon merkwürdig, 10% Miese auf einmal. Oder habe ich irgendwelche schlechte News verpasst?
Vielleicht Insider Verkauf?
Blackgold

versteht keiner, hat doch letzte woche einen positiven beitrag gegeben und die clinical trails sind auch alle im plan. Zumindest sehe ich das so.

mf

wird die Hana Bio demnächst abheben, weil im untergrund die zocker sammeln.
Ich denke die hat wirklich potential und deshalb bleib ich investiert.

mf

www.hanabiosciences.com/press-releases/070105.pdf

Geduld lange genug auf die Probe gestellt. Minus 36% sind genug. Jetzt wird verkauft. Nachdem der "Aktionär" in seinem Langfrist-Depot nachträglich einen SL gesetzt hatte und mitlerweile ausgestoppt wurde werde ich mich auch verabschieden. Der "Aktionär" hat nur lapidar mitgeteilt, dass der Wert mit Minus 35% ausgebucht worden sei. Leider keine Angaben von Gründen des Niedergangs. Man kann nur vermuten, dass da in der vielgepriesenen Pipeline etwas nicht stimmt. Naja, Game Over.
Grüße vom Waleshark.

Heute wieder +11,29 %,

Kopie e-mail trigger
HANA BIOSCIENCES ANNOUNCES 2007 CORPORATE GOALS



·         2006 achievements included completing pivotal trials and NDA filing for Zensana™, strengthening pipeline with the addition of four drug candidates, and expanding investor reach with a NASDAQ Global Market listing

·         2007 goals include commercially launching Zensana™, initiating pivotal trial for Marqibo in ALL, and Talotrexin Phase II in NSCLC and ALL

·         Discontinued IPdR (ropidoxuridine) from its pipeline of seven product candidates



South San Francisco, CA (January 8, 2007) – Hana Biosciences (NASDAQ: HNAB), a biopharmaceutical company focused on advancing cancer care, today reviewed its 2006 progress, announced corporate goals for 2007, and announced its decision to discontinue development of IPdR (ropidoxuridine).



“2006 was an exciting year in terms of clinical progress, business development and building core competencies in key areas of focus in oncology.   We completed pivotal trials and filed a New Drug Application (NDA) for Zensana™, significantly strengthened our pipeline with four additional drug candidates, and expanded investor reach with a NASDAQ listing,” stated Mark Ahn, President and CEO. “We’re very excited about our 2007 goals, including the launch of our first product, Zensana™, initiating pivotal trials for Marqibo in ALL, and initiating Talotrexin Phase 2 trials in NSCLC and ALL.”

more look here
www.hanabiosciences.com/press-releases/070108.pdf

sieht es etwas besser aus und langfristig hoffe ich, dass wir wieder im Bereich um die 6,30 € kommen werden.
Hat jemand neue news? Danke.

In den USA
6,20 USD  (+0,45/+7,83%)Kurs von 14.02. | 17:44:27

Frankfurt
4,87 EUR  (+0,27/+5,87%)
     ISIN:US40963P1057§Letzt. Volumen: 500
Kurs von 20.02. | 12:16:41

sieht ja ganz gut aus

ich bin auch überrascht worden.
Ich glaube dennoch an den Wert, man wird sicher Geduld haben müssen.

3,87 EUR  (+0,18/+4,88%)
Kurs von 22.02. | 13:47:42 in Frankfurt

all time low....

• Marqibo®: Phase 2 relapsed ALL to commence; Phase 3 registration trials planned in
first-line ALL and NHL
• Talvesta™: Program on hold pending toxicology studies
• Zensana™: New formulation under active investigation and scale-up
• Management to host a conference call today at 8:30 a.m. EDT, 5:30 a.m. PDT


ganze Meldung unter www.hanabiosciences.com/press-releases/070323.pdf

bald 1.0€   dann gehe ich rein..

mamamia...

bald 1,0€   oder  0,01 cent